US FDA Signals New COVID-19 Vaccines Could Be Authorized With Just Immunogenicity Studies

As FDA lowers some expectations on timing of booster shots, agency’s outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.